NAPD regimen for patients with recurrent refractory diffuse large B-cell lymphoma.
10.11817/j.issn.1672-7347.2018.07.009
- Author:
Chenghui HUANG
1
;
Hui WU
1
;
Haihua ZHU
1
;
Lan LIU
1
;
Ruifang TIAN
1
;
Cong XU
1
;
Xiaofei LI
1
;
Lihui WANG
1
;
Ke CAO
1
;
Peiguo CAO
1
Author Information
1. Department of Oncology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
adverse effects;
therapeutic use;
Cisplatin;
administration & dosage;
Cytarabine;
administration & dosage;
Dexamethasone;
administration & dosage;
Humans;
Induction Chemotherapy;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
mortality;
Neoplasm Recurrence, Local;
drug therapy;
mortality;
Retrospective Studies;
Salvage Therapy;
methods;
Treatment Outcome;
Vinblastine;
administration & dosage;
analogs & derivatives;
Vinorelbine
- From:
Journal of Central South University(Medical Sciences)
2018;43(7):754-759
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the clinical efficacy and toxicities for the NAPD regimen (vinorelbine, cytarabine, cisplatin, and dexamethasone) in the treatment of recurrent refractory diffuse large B-cell lymphoma.
Methods: A total of 30 patients identified with recurrent refractory diffuse large B-cell lymphoma were enrolled in this retrospective study. The curative efficacy of NAPD regimen was evaluated after 2 consecutive cycles. The toxicities and adverse reaction were evaluated after 1 cycle. The objective response rate (ORR), overall survival (OS), progress free survival (PFS), and the rates of 1, 2, and 4-year OS and PFS were analyzed. The prognosis was evaluated with univariate analysis.
Results: The ORR was 56.7% and clinical benefit rate (CBR) was 83.3% after 2 cycles. Five patients achieved complete remission, 12 achieved partial remission, and 8 achieved stable disease. The median OS was 22 (1.5-140) months. The 1, 2, and 4-year OS rates were 59.1%, 48.2%, and 40.2%, respectively. The median PFS was 14 (1.5-140) months. The 1, 2 and 4-year PFS rates were 56.3%, 42.2%, and 31.7%, respectively. The main adverse reaction was myelosuppression. Three patients suffered from grade III-IV leukopenia and 1 thrombocytopenia. Grade I-II gastrointestinal toxicity was 20%. No heart, liver, and kidney damages at grade III-IV were observed.
Conclusion: The NAPD regimen is effective and its toxicity is well tolerated for the treatment of recurrent refractory diffuse large B-cell lymphoma. It is a salvage chemotherapy regimen worth to be verified.
